The Oncology Institute Featured on Four Abstracts at ASCO 2023 Annual Meeting Read More » May 31, 2023
The Oncology Institute Enrolls Nation’s First Two Patients in a Phase 3 Open-Label, Randomized Clinical Trial of Pirtobrutinib Read More » September 29, 2022
